Lumateperone Transdermal Patch Polymer Matrix Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal therapeutic systems for lumateperone lack high adhesiveness, physical and chemical stability, and consistent permeation over several days, and they often require permeation enhancers that can cause skin irritation and complicate the development process.
Innovation Solution
A transdermal therapeutic system comprising a polymer matrix with a polyacrylate containing free hydroxy groups, a mixture of acrylate and silicone polymers, or a silicone polymer, which provides high adhesiveness and stability, and optionally includes an adhesive layer and a membrane layer to control the release of lumateperone, eliminating the need for permeation enhancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If permeation enhancers are used to achieve sufficient permeation, then permeation properties are improved, but skin irritation increases and device complexity increases
Solution Approach 1:
The patent removes permeation enhancers from the transdermal therapeutic system formulation entirely. Instead of adding substances to enhance permeation, the invention relies on the inherent permeation characteristics of the polymer matrix and adhesive layer combination, thereby eliminating skin irritation caused by enhancers while maintaining sufficient drug delivery
Solution Approach 2:
The patent employs a disposable transdermal patch design where the polymer matrix and adhesive layer work together as a single integrated system. The adhesive layer is formulated to provide both adhesion and controlled permeation without requiring additional enhancer components, simplifying the system while maintaining effectiveness
2Reliability
If permeation enhancers are used to achieve sufficient permeation, then permeation properties are improved, but development complexity increases
Solution Approach 1:
The patent extracts and removes permeation enhancers from the formulation, thereby eliminating the need for their quantification, control, and in vivo performance demonstration as required by regulatory guidelines. This significantly simplifies the development and regulatory process while maintaining adequate permeation through the polymer matrix-adhesive layer system
Solution Approach 2:
The adhesive layer is designed to perform multiple functions simultaneously: providing adhesion to the skin, controlling drug permeation, and eliminating the need for separate permeation enhancers. This multi-functionality reduces the number of components that require development and regulatory approval
3Duration of action of stationary object
If a multi-day patch is designed to improve patient compliance, then duration of action is improved, but adhesiveness requirements increase
Solution Approach 1:
The patent uses a composite system consisting of a polymer matrix combined with an adhesive layer to achieve both long duration of use and high adhesiveness. The adhesive layer is specifically formulated to maintain strong adhesion over multiple days while the polymer matrix provides controlled permeation, resolving the contradiction between duration and adhesiveness requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high and consistent permeation of lumateperone over 2 to 4 days without the use of permeation enhancers, maintaining adhesiveness and stability during storage, thereby improving patient compliance and reducing regulatory and development challenges.
Implementation Method 1
The system achieves high and consistent permeation of lumateperone over 2 to 4 days without the use of permeation enhancers
Implementation Method 2
maintaining adhesiveness and stability during storage
Data Source
Figure 1A~1D
Figure 2
Figure 3
AI summary
The present invention concerns a transdermal therapeutic system for administering the active ingredient lumateperone comprising a backing layer and at least one active ingredient containing layer, comprising the active ingredient in free base or salt form embedded in a polymer matrix, wherein the polymer matrix comprises a polymer selected from the group consisting of (1) a polyacrylate, preferably a polyacrylate containing free hydroxy groups, (2) a mixture of a polyacrylate and a silicone polymer, and (3) one or more silicone polymer. The transdermal therapeutic system may further comprise an adhesive layer, a membrane layer, and a release liner.